The recent realization by the market has made the Arch chart look incredible, but lets no forget that we are extremely undervalued compared to our peers.

Current Market cap 145 mil US

We are waiting on Phase II Human Clinical Trial Data by a third party for a 20 billion a year unmet market.

BLU is currently 578 mil market cap for Chronic Cough (Phase 2)

VXRT is currently 888 mil market cap  US Oral Vaccines

SAVA is 2 billion US market cap for Blood Cancer (Phase 2)

CYDY is 1.1  billion US market cap for Antibodies

TRIL was 2.2 billion buyout (Phase 2)

As we wait on data, there is no reason why we are not at a 600 million market cap of $9.68. We have fully patented new mechanism of action with a drug library. IMHO we will be 10x this current price if data deems it worthy.